Millions of Americans receive allergen immunotherapy (AIT) or “allergy shots” annually to address allergic rhinitis.1 AIT treatments have been provided for more than a century and until recently had been delivered by using an aseptic technique.1 In a prior retrospective study, more than 3000 patients with no AIT-associated skin and soft-tissue infections (SSTIs) were identified.1 However, recently, there has been renewed concern about preparation at compounding pharmacies that have led to infection outbreaks.
Read Full Article
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου